The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease

REFERENCES

• Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364: 613–620.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, : Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532–555.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, : The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 2645–2653.
   PubMed Web of Science ®Google Scholar
• Agusti AG: Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 367–370.
   PubMedGoogle Scholar
• Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2: 619–626.
   PubMedGoogle Scholar
• Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, : IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101: 311–320.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, : Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324: 73–76.
   PubMed Web of Science ®Google Scholar
• Maggio M, Guralnik JM, Longo DL, Ferrucci L: Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61: 575–584.
   PubMed Web of Science ®Google Scholar
• Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(Suppl 2):S3.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, : Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82: 4196–4200.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374: 1–20.
   PubMed Web of Science ®Google Scholar
• Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005;175: 3463–3468.
   PubMed Web of Science ®Google Scholar
• Quinton LJ, Jones MR, Robson BE, Simms BT, Whitsett JA, Mizgerd JP: Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia. Am J Respir Cell Mol Biol. 2008;38: 699–706.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55: 114–120.
   PubMed Web of Science ®Google Scholar
• Song W, Zhao J, Li Z: Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J (Engl ). 2001;114: 1140–1142.
   PubMed Web of Science ®Google Scholar
• Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ: High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97: 1299–1302.
   PubMed Web of Science ®Google Scholar
• van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, : C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179: 375–382.
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175: 250–255.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59: 574–580.
   PubMed Web of Science ®Google Scholar
• Doz E, Noulin N, Boichot E, Guenon I, Fick L, Le BM, : Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008;180: 1169–1178.
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, : Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368: 339–342.
   PubMed Web of Science ®Google Scholar
• D′hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA: Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J. 2005;26: 204–213.
   PubMed Web of Science ®Google Scholar
• Bracke KR, D′hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel WA, : Cigarette smoke-induced pulmonary inflammation, but not airway remodeling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy. 2007;37: 1467–1479.
   PubMed Web of Science ®Google Scholar
• Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA: Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med. 2001;193: 51–60.
   PubMed Web of Science ®Google Scholar
• Vermaelen K, Pauwels R: Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A. 2004;61: 170–177.
   PubMed Web of Science ®Google Scholar
• Thurlbeck WM: Measurement of pulmonary emphysema. Am Rev Respir Dis. 1967;95: 752–764.
   PubMed Web of Science ®Google Scholar
• D′hulst AI, Maes T, Bracke KR, Demedts IK, Tournoy KG, Joos GF, : Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? Respir Res. 2005;6: 147.
   PubMedGoogle Scholar
• Wigmore SJ, Fearon KC, Maingay JP, Lai PB, Ross JA: Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273: E720–E726.
   PubMed Web of Science ®Google Scholar
• D′hulst AI, Bracke KR, Maes T, De Bleecker JL, Pauwels RA, Joos GF, : Role of tumour necrosis factor-alpha receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema. Eur Respir J. 2006;28: 102–112.
   PubMed Web of Science ®Google Scholar
• La Cava A, Matarese G: The weight of leptin in immunity. Nat Rev Immunol. 2004;4: 371–379.
   PubMed Web of Science ®Google Scholar
• Yu M, Zheng X, Witschi H, Pinkerton KE: The role of interleukin-6 in pulmonary inflammation and injury induced by exposure to environmental air pollutants. Toxicol Sci. 2002;68: 488–497.
   PubMed Web of Science ®Google Scholar
• Demoor T, Bracke KR, Maes T, Vandooren B, Elewaut D, Pilette C, : Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis. Eur Respir J. 2009;34: 405–416.
   PubMed Web of Science ®Google Scholar
• Demoor T, Bracke KR, Vermaelen KY, Dupont L, Joos GF, Brusselle GG: CCR7 modulates pulmonary and lymph node inflammatory responses in cigarette smoke-exposed mice. J Immunol. 2009;183: 8186–8194.
   PubMed Web of Science ®Google Scholar
• Bao S, Husband AJ, Beagley KW: B1 B cell numbers and antibodies against phosphorylcholine and LPS are increased in IL-6 gene knockout mice. Cell Immunol. 1999;198: 139–142.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80: 227–236.
   PubMed Web of Science ®Google Scholar
• Wouters EF, Creutzberg EC, Schols AM: Systemic effects in COPD. Chest. 2002;121: 127S–130S.
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359: 2355–2365.
   PubMed Web of Science ®Google Scholar
• Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, : Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994;180: 1243–1250.
   PubMed Web of Science ®Google Scholar
• Gosker HR, Langen RC, Bracke KR, Joos GF, Brusselle GG, Steele C, : Extrapulmonary manifestations of COPD in a mouse model of chronic cigarette smoke exposure. Am J Respir Cell Mol Biol. 2008;40: 710–716.
   PubMed Web of Science ®Google Scholar
• Fäldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO: Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology. 2004;145: 2680–2686.
   PubMed Web of Science ®Google Scholar
• Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, : Interleukin-6-deficient mice develop mature–onset obesity. Nat Med. 2002;8: 75–79.
   PubMed Web of Science ®Google Scholar
• Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA: Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287: E182–E187.
   PubMed Web of Science ®Google Scholar
• Hoene M, Weigert C: The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9: 20–29.
   PubMed Web of Science ®Google Scholar
• Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, : Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004;114: 582–588.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yoshizaki K, Kishimoto T, Ito H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164: 4878–4882.
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, : Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6: 583–588.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J: Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2008;68: 1580–1584.
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, : A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn′s disease. Gastroenterology. 2004;126: 989–996.
   PubMed Web of Science ®Google Scholar
• Barnes PJ: Emerging pharmacotherapies for COPD. Chest. 2008;134: 1278–1286.
   PubMed Web of Science ®Google Scholar